Intellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year Low – Time to Sell?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares reached a new 52-week low on Friday . The company traded as low as $13.95 and last traded at $13.97, with a volume of 3666342 shares trading hands. The stock had previously closed at $15.12.

Wall Street Analyst Weigh In

A number of research analysts recently commented on NTLA shares. Stifel Nicolaus lowered their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research note on Wednesday, September 11th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. Chardan Capital lowered their price objective on shares of Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. The Goldman Sachs Group decreased their price target on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Finally, Citigroup cut their price objective on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $55.36.

Intellia Therapeutics Price Performance

The company has a fifty day moving average of $18.75 and a 200-day moving average of $22.09. The firm has a market capitalization of $1.42 billion, a PE ratio of -2.57 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. During the same quarter in the previous year, the business posted ($1.38) EPS. The firm’s quarterly revenue was down 24.1% on a year-over-year basis. Equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.13 EPS for the current year.

Insider Buying and Selling at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. This represents a 4.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. Blue Trust Inc. boosted its stake in shares of Intellia Therapeutics by 1,664.3% during the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after buying an additional 1,398 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after buying an additional 1,550 shares during the last quarter. Eastern Bank acquired a new position in shares of Intellia Therapeutics during the 3rd quarter worth about $41,000. Values First Advisors Inc. acquired a new position in shares of Intellia Therapeutics during the 3rd quarter worth about $54,000. Finally, First Horizon Advisors Inc. boosted its stake in shares of Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after buying an additional 472 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.